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Valeur du F-18-FDG PET/CT pour déterminer la nature maligne des 
épanchements chez les patients avec cancer (Value of F-18-FDG 
PET/CT for determining malignant pleural effusion in patients with cancer) 
· Les épanchements pleuraux sont fréquents chez les patients porteurs de cancer et 
déterminer s'ils sont de nature tumorale ou non relève d'une grande importance clinique, 
particulièrement pour le groupe des carcinomes pulmonaires NON à petites cellules 
(NSCLC). Le PET /CT s'est montré d'une grande utilité et est actuellement indiscutablement 
reconnu comme outils nécessaire dans la prise en charge et notamment la stadification et le 
suivi des cancers, et particulièrement des cancers pulmonaires. Sa capacité à pouvoir 
distinguer les épanchements pleuraux malins des épanchements pleuraux non tumoraux, 
«bénins» n'est pas précisément connue et n'a pas jusqu'à présent été investiguée de 
manière approfondie. 
Nous avons examiné la captation du FDG (indice SUVmax) des 
épanchements pleuraux de 50 PET/CT réalisés chez 47 patients (29 hommes, 18 femmes, 
60±16 ans) avec épanchements pleuraux et cancer connu (24 NSCLC, 7 lymphomes, 5 
cancer du sein, 4 GIST, 3 mésothéliomes, 2 cancer ORL, 2 tératomes malins, 1 carcinome 
colorectal, 1 carcinome oesophagien, 1 mélanome). Ces résultats ont été corrélés aux 
résultats des examens cytopathologiques réalisés après ponction de ces mêmes 
épanchements dans un intervalle médian de 21 jours (interquartile range -3 to 23). 
L'examen du liquide d'épanchement comportait la mesure du pH, la distribution relative 
des différents éléments cellulaires (macrophages, neutrophiles, éosinophiles, basophiles, 
lymphocytes, plasmocytes), la numération cellulaire et bien entendu présence de cellules 
tumorales. 
, Parmis les épanchements, 17 étaient malins (34%) (6 NSCLC, 5 lymphomes, 2 
cancers mammaires, 2 mésothéliomes, 2 tératomes malins). 
Les SUV étaient plus élevés dans les épanchements malins que dans les épanchements 
bénins [3.7 (95%IC 1.8-5.6) vs. 1.7 g/ml (1.5-1.9), p = 0.001], avec une corrélation entre les 
épanchements malins et le SUV (coefficient de Spearman p = 0.50, p = 0.001). Il n'a pas été 
observé de corrélation entre aucun des autres paramètres cyptopathologiques ou 
radiologiques analysé (aire sous la courbe ROC 0.83 ± 0.06). 
En utilisant un seuil du SUV de 2.2-mg/l, 12 examens PET /CT étaient interprétés comme 
positifs and 38 comme négatifs avec une sensibilité et une spécificité, valeur prédictive 
positive et négative de 53%, 91 %, 75% and 79% respectivement. Concernant le groupe des 
NSCLC seulement (n = 24), aire sous la courbe ROC était de 0.95 ± 0.04. Sept examens 
étaient considérés comme positifs et 17 comme négatifs avec une sensibilité, une spécificité, 
valeur prédictive positive et négative de 83%, 89%, 71 et 94% respectivement. 
: Le PET /CT peut aider à différencier la nature bénigne ou maligne des 
épanchements avec une haute spécificité chez les patients avec tumeur connue, en 
particulier dans un contexte de carcinome NON à petites cellules. 
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Pleural effusion, tumour, PET/CT, FDG 
Pleural effusion is common in cancer pa-
tients and to determine its ma lignant origin is 
of huge clinical significance. PET/CT with 
18F-FDG is of diagnostic value in staging and 
follow-up, but its ability to differentiate be-
tween malignant and benign effusions is not 
precisely known. methods:We exam-
ined 50 PET/CT from 47 patients (29 men, 18 
women, 60±16 years) with pleural effusion 
and known cancer (24 NSCLC, 7 lymphomas, 5 
breasts, 4 GIST, 3 mesotheliomas, 2 head and 
neck, 2 malignant teratoma, 1 colorectal, 1 
oesophageal, 1 melanoma) for FDG uptake in 
the effusions using SUV max· This was cor-
related to cytopathology performed after a 
median of 21 days (interquartile range -3 to 
23), which included pH, relative distribution 
(macrophages, neutrophils, eosinophils, baso-
phils, lymphocytes, plasmocytes), and abso-
lute cell count. Malignant cells were 
found in 17 effusions (34%) (6 NSCLC, 5 lymp-
homas, 2 breasts, 2 mesotheliomas, 2 malig-
nant teratomas). SUV in malignant effusions 
were higher than in benign ones [3. 7 (95%CI 
1.8-5.6) vs. 1. 7 g/ml (1.5-1.9), p = 0.001 J, 
with a correlation between malignant effu-
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sion and SUV (Spearman coefficient p = 0.50, p 
= 0.001), but not with other cytopathological 
or radiological parameters (ROC area 
0.83±0.06). Using a 2.2-mg/I SUV threshold, 
12 PET/CT studies were positive and 38 
negative with sensitivity, specificity, positive 
and negative predictive values of 53%, 91 %, 
75% and 79%, respectively. For NSCLC only (n 
= 24), ROC area was 0.95±0.04, 7 studies 
were positive and 17 negative with a sensitiv-
ity, specificity, positive and negative predictive 
values of 83%, 89%, 71 and 94%, respectively. 
PET/CT may help to differentiate 
the ma lignant or benign origin of a pleural effu-
sion with a high specificity in patients with 
known cancer, in particular NSCLC. 
Pleuraerguss, Tumor, PET/Cf, FDG 
Pleuraerguss ist ein haufiges Symptom, 
auch bei onkologischen Patienten, oh ne dass es 
sich obligat um eine maligne Âtiologie handeln 
muss. Der Charakter des Ergusses und seine Pa-
thogenese sind jedoch für weitere therapeuti-
sche MaBnahmen entscheidend. Die Wertigkeit 
der 18F-FDG-PET/CT für Staging und Nachsorge 
ist unbestritten, ob aber die PET zwischen ma-
zy1opatl1ologisd1en 
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lignem und benignem Erguss unterscheiden 
kann wurde noch wenig untersucht. v:iti<>nt''" 
untersuchten 47Tumor-Pa-
tienten (29 Manner, 18 Frauen, 60± 16 Jahre) 
mit Pleuraergüssen [24 nicht-kleinzellige Lun-
genkarzinome (NSCLC), 7 Lymphome, 5 Mam-
makarzinome, 4 GIST, 3 Mesotheliome, 2 
HNO-Karzinome, 2 maligne Teratome, 1 Ko-
lon/Rektumkarzinom, 1 ôsophaguskarzinom, 
1 Melanom) mit insgesamt 50 PET/CT. Die 
FDG-Konzentration in den Ergüssen wurde 
anhand Messungen des SUVmax• normalisiert 
auf das Kiirpergewicht geschatzt. Die Pleura-
ergüsse wurden aile punktiert, im Mittel 21 
Tage (lnterquartilbereich -6 bis +23 Tage) 
nach der PET-Untersuchung, und zytologisch 
untersucht, ebenso wurde die zellulare Zu-
sammensetzung (Makrophagen, Neutrophile, 
Eosinophile, Basophile, Lymphozyten, Plas-
mozyten) quantifiziert und der pH-Wert be-
stimmt. Siebzehn Pleuraergüsse 
(34%) enthielten maligne Zellen (6 NSCLC, 5 
Lymphome, 2 Mammakarzinome, 2 Mesothe-
liome, 2 maligne Teratome) und zeigten einen 
hoheren SUV max·Wert ais Ergüsse oh ne klare 
maligne Ursache [3,7 (95%CI 1,8-5,6) vs. 1,7 
g/ml (1,5-1,9), p = 0,001 ]. Die malignen Pleu-
raergüsse korrelierten lediglich mit dem SUV 
(Spearman-Koeffizient p = 0,50, p = 0,001), 
jedoch nicht mit zytologischen oder radiologi-
schen Parametern (ROC-Area 0,83±0,06). Bei 
einer SUV max·Schwelle von 2,2 mg/I, waren 12 
PET/CT Untersuchungen positiv und 38 nega-
tiv, mit 53% Sensitivitat, 91 % Spezifizitat, 
was sich in einen 75% positiven und 79% ne-
gativen pradiktiven Wert übersetzt. Analysie-
ren wir lediglich NSCLC (n = 24) wird eine 
ROC von 0,95±0,04 errechnet, 7 Unter-
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suchungen waren positiv und 17 negativ, mit 
83% Sensitivitat, 89% Spezifizitat, und so-
mit 71 % positivem und 94% negativem pra-
diktivem Wert. Die PET/CT 
erlaubt mit hoher Spezifizitat zwischen mali-
gnen und benignen Pleuraergüssen zu unter-
scheiden, insbesondere bei NSCLC. Der ne-
gative pradiktive Wert von >90% ist klinisch 
von Bedeutung. 
Pleural effusion is defined as an accumu-
lation of> 15-20 ml of fluid in the pleural 
space (1). It is found in a wide range of 
clinical conditions (1), such as 
e heart failure, 
<11 inflammatory or infectious disease, 
<11 cancer, or 
e may be ofrenal or hepatic origin (1). 
In patients over 50 years old, about 40% of 
clinically significant effusions are due to 
malignancy, most commonly lung and 
breast cancer, lymphoma, mesothelioma, 
oesophageal or gastric cancer, ovarian car-
cinoma and germ cell tumours (1). In 
cancer patients, determining whether ma-
lignant cells are present in a pleural effu-
sion is of great clinical significance, as it de-
termines therapeutic attitude and prog-
nosis. 
Malignant effusions are caused by local ex-
tension of Jung cancer or by metastatic dis-
ease and usually represent an advanced 
stage. 
The presence of malignant cells is deter-
mined by cytopathological examination of 
thoracocentesis obtained effusion fluid 
(18). Fourteen percent of patients with 
lung cancer have pleural effusion when di-
agnosis is first established (30). In the latest 
7th edition of the AJCC TNM staging 2010 
(8), malignant pleural effusion in lung 
cancer has been reclassified to a worse 
prognosis group, moving from T4 to Ml 
category, i.e. from stage IVA to IVB. Never-
theless, pleural effusions in cancer patients 
are not always malignant (8). 
Hybrid imaging with positron emission 
tomography/ computed tomography (PET/ 
CT) has proved to be of high diagnostic 
value in staging and follow-up of patients 
Nuklearmedizin 5/2012 
with lung cancer (10, 11), as well as other 
tumours such as lymphoma, colorectal, 
breast and head and neck cancers, among 
others ( 24). 
The uptake of 18F-fluorodeoxyglucose 
(FDG) during PET imaging, as measured 
by the maximum standardized uptake 
value reported for body weight (SUV maJ 
has been defined for solid tumours or 
masses and has a strong predictive value for 
determining their benign or malignant na-
ture. Although PET /CT is becoming a stan-
dard procedure in cancer patient investi-
gations, only a few studies have tried to 
evaluate pleural disease and effusions with 
PET or PET/CT (2, 6, 7, 9, 12, 16, 27). How-
ever, no study has presented a correlation 
between imaging and the cytopathological 
characteristics of the thoracocentesis 
liquid, which is important to understand 
the respective roles of inflammatory and 
malignant component of the effusion on 
SUV values. Indeed, it is known that the 
uptake of FDG is not specific of malignant 
cells, but can also be found in inflamma-
tory cells such as lymphocytes, monocytes 
and macrophages (14, 17, 22). Thus, we 
aimed at determining the value of PET /CT 
in non-invasively predicting 
@ the malignant or benign nature of pleu-
ral effusion in cancer patients at initial 
staging or during follow-up, as well as 
the effect of the cytopathological char-
acteristics on the FDG uptake. 
Data from the University Institute of Pa-
thology and from the Nuclear Medicine 
Department of the Lausanne University 
Hospital were cross-matched for patients 
undergoing thoracocentesis with cytologi-
cal examination of effusion fluid and PET/ 
CT between June 2004 and December 2006. 
Only patients having both cytological 
evaluation of the fluid and imaging pro-
cedures within a 60-day interval were in-
cluded in this study. The Institutional Re-
view Board issued a waiver for patient in-
formed consent for this retrospective study. 
All pleural effusions were examined 
according to a standard protocol. When 
received, effusion fluid quantity was deter-
mined. The pH was measured when possi-
ble ( delayed arrival of the fluid precluded 
this analyses in some cases) and cell numer-
ation was performed. The pH was 
measured with a laboratory millivoltmeter 
PHM210 with a pHC3006-9 electrode 
(Radiometer Analytical, Villeurbanne, 
France). 
Absolu te cell count was assessed using a 
Neubauer haemocytometer chamber. After 
centrifugation at 2000 rpm for 10 minutes, 
six smears were made. Three were immedi-
ately fixed with Delaunay and Pap stained. 
The three others were air-dried from which 
two were stained with MGG (May-Gruen-
wald Giemsa). When cell concentration 
was low, additional cytospins were ob-
tained. Cel! distribution (macrophages, 
neutrophils, eosinophils, basophils, lymp-
hocytes, plasma cells) and presence or ab-
sence of atypical or malignant cells was as-
sessed. When needed, cellblocks were 
made, and standard immunostains (Cal-
retinin, WT-1, BerEP4, B72.3, TTF-1, hor-
mone receptors, lymphoid markers, etc.) 
were performed to determine the reactive 
or tumoural nature of the liquid as well as 
the origin of any atypical/tumour cells ob-
served. All smears and immunostained 
slides were initially reviewed by a senior cy-
topathologist. Results of the routinely per-
formed cytological examinations were col-
lected and cytological slides were reviewed 
to complete any missing data. 
PET/CT 
Whole-body PET/CT was acquired 60 min 
after intravenous bolus injection ofFDG (5 
MBq/kg body weight). Patients were asked 
to refrain from eating ;:::6 hours before PET 
and blood glucose at injection was <8.3 
mmol/l (Discovery LS scanner, GE Health-
care, Milwaukee, Wisconsin). Attenuation 
correction was performed using a low-dose 
unenhanced CT (140 keV, 80 mA, slice 
thickness 5 mm). 
© Schattauer 2012 
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Enhanced CT 
All enhanced CT were performed for inves-
tigating increasing dyspnoea symptoms 
using the same pulmonary embolism 
protocol on an 8- or 16-detector CT 
scanner (GE Healthcare, Milwaukee, Wis-
consin). Thirty seconds after intravenous 
(IV) iodinated contrast medium injection 
(80 ml at 3 ml/s, 300 mgl/ml, Accupaque®, 
Iohexol, GE Healthcare) data acquisition 
was performed (120 keV, 260mA, pitch 
1.375, collimation 0.675, axial slice recon-
struction 5 mm/5 mm for standard algo-
rithm and 1.25 mm/1 mm for lung algo-
rithm). 
lmaging study analysis 
PET/CT and enhanced CT, when available, 
were reviewed. On PET/CT, FDG uptake 
was measured using the maximum stan-
dardized uptake value corrected for body 
weight (SUV max in g/ml) in pleural effu-
sions or in pleural lesions using a 1.2 cm 
circular region of interest and avoiding the 
thoracic wall and the Jung parenchyma; in 
larger effusions, the region of interest was 
placed in the centre of the effusion. Pleural 
liquid quantity was estimated using a di-
chotomized scale ( <500 ml, ;:::500 ml) based 
on the absence or presence of pleural effu-
sion on more than half on the Jung length 
results variable 
[adapted from (29)]. Enhanced CT was 
used to determine presence of pleural 
lesions or serosal enhancement and their 
Hounsfield density (HU) was measured, as 
well as the one of the effusion fluid (15). 
Cytopathological examination of pleural 
effusion fluid after thoracocentesis is con-
sidered the most accurate procedure to de-
termine the benign or malignant nature of 
an effusion, and was considered as the so-
called gold standard in our study (8). 
The ability of SUV to determine the pres-
ence of malignant cells in pleural effusion 
was evaluated using receiver operating char-
acteristics (ROC) curves and computing 
sensitivity, specificity, negative (NPV) and 
positive predictive value (PPV) as compared 
to the gold standard (cytopathology) (23). 
The effect of other cytopathological para-
meters, especially inflammatory cells, as well 
as pleural liquid quantity, CT density and 
contrast enhancement was examined. Sig-
nificance was considered for p < 0.05. 
In total, 50 18F-FDG PET/CT studies and 
cytological analysis of the thoracocentesis 
effusion 
were performed in 47 patients with known 
cancer. There were 29 men and 18 women 
with a mean age of 60 ± 16 years, who were 
investigated for 
@ non-small cell lung cancer (NSCLC) 
(n = 24, 48%), 
@ lymphoma (n = 7, 14%), 
@ breast cancer (n = 5, 10%), 
@ GIST (n = 4, 8%), 
@ mesothelioma (n = 3, 6%), 
e head and neck cancer (n = 2, 4%), 
<11 malignantteratoma (n = 2, 2%), 
@ colorectal carcinoma (n = l, 2%), 
@ oesophageal carcinoma (n = 1, 2%) and 
@ melanoma (n = 1, 2%). 
Thoracocentesis was performed within a 
median interval of 21 days (interquartile 
range -6 to 23 days) after PET /CT imaging; 
in a few examinations (n = 18), it was per-
formed before the PET/CT. 
Out of the 50 cytological analyses, 
<11 33 (66%) were benign and 
@ 17 (34%) were malignant. 
Of the latter, 6 (35%) were positive for 
NSCLC, 5 (29%) for lymphomas, 2 (12%) 
breast cancer, 2 (12%) for mesothelioma 
and 2 (12%) for malignant teratoma. De-
p 
Results of 50 
thoracocentesis 
liquid samples, 
grouped according to 
the final diagnosis of 
benign versus 
malignant effusions 
mean±SD (range) benign (n = 33) malignant (n = 17) 
© Schattauer 2012 
cyto-
pathology 
PET/Cl; 
enhanced 
CT 
thoracocentesis volume (ml) 
absolute cell count (109/1* 
effusion pH 
relative distribution (%) macrophages 
neutrophils 
eosinophils 
basophils 
lymphocytes 
plasmocytes 
others 
SUV (g/ml) 
effusion quantity (ml) 0-500 
estimate (%) ;::: 500 
CT density (HU)il effusion 
parietal 
227±353 (2-1400) 296±443 (5-1880) 
1.2±1.1 (0.075-4.3) 3.3±4.9 (0.20-15.2) 
7.6±0.3 (7.3-8.3) 7.5±0.3 (7.0-7.8) 
20±23 (0-82) 14±11 (0-34) 
22±26 (0.5-89) 12±22 (0-85} 
1.9±4.1 (0-20.5} 2.4±5.1 (0-19) 
0.02±0.09 (0-0.5) 0 (0-0) 
50±28 (2-97) 57±32 (3-99) 
0.36±1.1 (0-6) 0.53±1.7 (0-7) 
0.16±1.0 (0-6) 2.6±10 (0-42) 
1.7±0.6 (0.6-3.9) 3.7±3.8 (1.3-16) 
18/33 (55%) 6/17 (35%) 
15/33 (45%) 11117 (65%) 
9±6 (-8-20) 11±3 (5-15) 
18±8 {7-40) 18±3 (14-21) 
*llavailable in a subset of patients (effusions *n = 30, #n = 24); SUV: standardized uptake value 
0.18 
0.21 
0.32 
0.96 
0.21 
0.94 
0.47 
0.59 
0.70 
0.23 
0.001 
0.24 
0.41 
0.44 
Nuklearmedizin 5/2012 
Oownloaded !rom www.nuklearmedizin-online.de on 2012-05-15110: 10005146501IP:155.105.65.253 
Note: Uncorrected prao!, prepublished online 
For persona! or educational use only. No other uses without permission. Ali rights reserved. 
4 1. Letovanec et al.: PET/CT in pleural effusion 
Cytological examinations 
reactive effusion with reactive mesothelial 
cells (-7) in an inflammatory background (arrow-
head) (PAP stain, x400) 
malignant effusion with lung adenocarcinoma 
cells in aggregates presenting voluminous and 
vacuolated cytoplasm (PAP stain, x 400) 
lymphoma with malignant lymphoid cells in 
mitosis (-7) and atypical lymphocytes with deeply 
basophilie cytoplasm (arrowhead) 
(MGG stain, x600). 
tailed cytological characteristics of the be-
nign and malignant effusions are summar-
ized in li> Table 1. Except for the presence of 
atypical cells, there were no significant dif-
ferences among benign or malignant effu-
sions. Sorne of the cytological findings are 
illustrated for benign (li> Fig. lA) and ma-
lignant thoracocentesis liquid samples 
(.,.,,Fig. lB and lC). 
Nuklearmedizin 5/2012 
The PET/CT and enhanced CT are pres-
ented in li> Table 1. There was a significantly 
higher SUV in malignant effusions as com-
pared to benign effusions (.,.,, Tab. 2, ""'Fig. 
2). Ali other imaging characteristics were 
not significantly different between benign 
and malignant pleural effusions, notably 
the pleural effusion volume estima te, or the 
CT Hounsfield density of the effusion or 
parietal region. Ali enhanced CT (n = 24) 
were performed because of sudden respir-
atory symptoms onset, to exclude pulmon-
ary embolism. Three of the enhanced CT 
showed parietal pleural lesion with en-
hancement with a mean CT density of 
56 (47-65) HU and a mean SUV uptake of 
4.3 (2.2-8.6) g/ml; two of these, were diag-
nosed with malignant effusion. 
As illustration, ""'Figure 2 shows 
examples of PET/CT images for patients 
with a positive (.,.,,Fig. 2A) and negative 
(li> Fig. 2B) cytopathological examination 
for malignant cells in the effusion. 
effusion using SUV as the only indepen-
dent predictor (""'Fig. 3). The area un der 
the curve (AUC) was 0.81±0.07 (""'Fig. 
3A). Using a threshold of :2: 2.2 g/ml led to 9 
true positive, 30 true negative, 3 false posi-
tive and 8 false negative examinations. This 
allowed obtaining a 
e sensitivity of 53% (95%CI 28-77%), 
® specificityof91% (76-98%), 
e positive predictive value of 75% 
(43-95%), 
El> negative predictive value of 79% 
(63-90%). 
The corresponding odds ratio was 6.9 
(1.9-41) on logistic regression (p == 0.005). 
Nearly half of our population were patients 
with non-small cell Jung cancer (n = 24). 
We examined the performance of PET/CT 
SUV to determine the presence of malig-
nant cells in this population. Thus, for 
NSCLC, the AUC was excellent with 
0.94±0.05 (.,.,,Fig. 3B). Using the same 
threshold :2: 2.2 g/ml resulted in 5 true 
positive, 16 true negative, 2 false positive 
and 1 false negative examinations. This led 
to a 
e sensitivity of 83% (95%CI 36-99% ), 
® specificity of 89% ( 65-99% ), 
e positive predictive value of 71 % 
(29-96%), 
® negative predictive value of 94% 
(71-99%). 
The corresponding odds ratio was 16 
(1.7-151) on logistic regression (p == 
0.016). Finally, we tested separately the 
group of patients with cancers other than 
NSCLC and found a lower AUC of 
0.74±0.10, which led to a 
® sensitivityof36% (11-69%), 
® specificity of 93% ( 68-99% ), 
® positive predictive value of 80% 
(28-99%), 
® negative predictive value of 67% 
(43-85%). 
The association of cytopathological and 
imaging characteristics with the final diag-
nosis of malignant pleural effusion is pres-
ented in ""'Table 2. There was no significant 
correlation between any cytopathological 
parameters, except for a strong association 
of presence of malignant cells with SUV 
(Spearman p = 0.50, p < 0.001) and a trend 
for decreased neutrophils being associated 
with malignant cells. Inversely, we also 
found no significant association of PET/ 
CT SUV with any other cytopathological 
parameters or CT HU density of the effu-
sion or of the parietal part (li>Tab. 2). When 
analysed separately for the subgroup of pa-
tients with NSCLC, these associations re-
mained, with a much stronger correlation 
between SUV and the presence of malig-
nant cells (Spearman p == 0.66, p < 0.0001). 
For the subgroup of patients with cancer 
other than NSCLC, the correlation between 
SUV and the presence of malignant cells re-
mained, although it was weaker (Spearman 
p == 0.41, p == 0.041). 
We also performed a ROC analysis to 
predict the malignant nature of the pleural 
Malignant effusion in patients with known 
cancer is of clinical significance and usually 
represents advanced disease stage. PET/CT 
is a tool frequently used to help staging in 
oncologie patients. We showed that 
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® the uptake of FDG was significantly 
elevated in patients with malignant 
pleural effusion, 
® SUV was the only variable showing an 
association with the malignant nature of 
the thoracocentesis fluid on uni- and 
multivariate analyses. 
No other imaging or cytological parame-
ters were associated with malignant cells, 
even HU density on enhanced CT. Using a 
threshold of 2.2 g/ml allowed to accurately 
classifying 81 % of effusions wit~ .a .high 
specificity of 91 %, with a poor sens1t1V1ty of 
53%, however. When considering only pa-
tients with NSCLC, the same 2.2-mg/dl 
SUV threshold allowed to correctly classify 
94% of effusions, with a good specificity of 
89% and an excellent negative predictive 
value. This high negative predictive value is 
of huge clinical value, as the latest AJCC 
TNM staging for NSCLC would ?ut .a pa-
tient with malignant pleural effus10n m the 
worst-prognosis Ml group. The perform-
ances for the subgroup of patients with 
cancer types other than NSCLC were 
poorer, but a significant association existed 
only between SUV and the presence of ma-
lignant cells. . . 
In the literature, only two stud1es usmg 
PET /CT were reported so far for investigat-
ing pleural effusions (2, 16). Both st~~ies 
reported higher sensitivity of de.tern:mmg 
the presence of malignant effus10n m p~­
tients with NSCLC, but were methodolog1-
cally different by reporting ~he highest 
FDG uptake in the pleural reg10n (93 and 
88%, respectively). In our study, only three 
patients showed parietal lesions out of.the 
33 patients with positive parie~al e~us1?n, 
leaving the sensitivity of th1s cntenon 
under 10% in the study presented here. 
Only the study by Kim et al. did measure 
the SUV in the pleural effusion itself and 
determined a much lower sensitivity of 
29% with a very high specificity of 100% 
and an accuracy of 0.61 when using a 
threshold of SUV > 1.56 for malignancy on 
PET/CT (16). This was not suited to help 
differentiating the malignant or benign 
origin or pleural effusion, however. 
In the other study,Alkhawaldeh et al. did 
not measure the effusion SUV but only the 
pleural SUV. Yet, they found that d~al-time 
acquisition was useful and could mcrease 
© Schattauer 2012 
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cr PET/CT fusion and PET images . . 
woman '(69 years) with pulmonary adenocarcinoma showing a 3.5-g/ml-SUV pleural effusion w1th 
malignant cells (-7) 1 ff · t · · 
man (69 years) with oesophageal adenocarcinoma and a 1.2-g/ml-SUV pleura e us10n con ammg 
only macrophages and no malignant cells (*) 
Univariate association of cytological and imaging parameters with diagnosis of malignant 
effusion and standardized value uptake (SUV) 
variable ....:S::.!p:..:e::a.:..:rm.::.a::n~co:.:.r.:_re--la_t_io_n __ -:::::-:------
(n = 50) malignant cells p SUV P 
thoracocentesis volume 
absolute cell count* 
0.18 0.21 0.08 0.57 
effusion pH 
relative 
distribution 
(%) 
absolute 
cell count 
(109f1)* 
macrophages 
neutrophils 
eosinophils 
basophils 
lymphocytes 
plasmocytes 
others 
macrophages 
neutrophils 
eosinophils 
basophils 
lymphocytes 
plasmocytes 
others 
standardized uptake value 
effusion quantity estimate 
CT densityt effusion 
0.26 
-0.23 
-0.01 
-0.25 
-0.01 
-0.10 
0.08 
0,05 
0.17 
0.13 
-0.17 
-0.01 
-0.13 
0.16 
0.19 
0.25 
0.50 
0.18 
0.17 
parietal 0.16 
0.16 
0.33 
0.97 
0.09 
0.94 
0.48 
0.60 
0.71 
0.23 
0.47 
0.34 
0.98 
0.49 
0.39 
0.29 
0.18 
<0.001 
0.20 
0.42 
0.46 
0.04 0.82 
-0.01 0.96 
0.10 0.47 
-0.25 0.08 
0.08 0.58 
-0.05 0.71 
0.02 0.86 
0.02 0.91 
0.08 0.56 
0.02 0.92 
-0.18 0.34 
-0.06 0.74 
0.12 0.53 
0.03 0.88 
-0.10 0.61 
0.09 0.65 
1.00 
0.16 0.28 
0.10 0.61 
-0.14 0.50 
*tavailable in a subset of patients (effusions *n == 30, 1n - 24) 
the diagnostic accuracy (2). Whether this 
would hold true in pleural effusion SUV re-
main to be verified. Other studies using 
PET only investigated the value of pleural 
activity to define the malignant nature of 
ffu . s (7 9 l2 25 27) also showinghigh e Slün , > > > 'fi 
. . 't' (88 100%) and good spec1 -sens1tiv1 ies -
cities (67-94%). 
Only Toaff et al. investigated t~e upt~e 
in the pleural effusion of patient w1th 
Nuklearmedizin 5/2012 
. 0514650 j IP: 155.105.65.253 oownloaded from www.nuklearmedizin-online.de on 2012-05-15 j IO. 100 
Note: Uncorrected proof, prepublished online 
. . · Ali rights reserved. For persona! or educational use only. No other uses w1thout permission. 
6 1. Letovanec et al.: PET/CT in pleural effusion 
extra-pleural primary malignancies using a 
1·7-g/ml SUV threshold to find a sensitivity 
of 43% with a 70% specificity and an accu-
racy of 55% (27), Interestingly, they report 
on an already proposed criteria (28) based 
on a higher FDG uptake than lung on non-
atte.nuatio~ corrected PET images being as-
sociated w1th a high probability of malig-
nant effusion. In summary, we found 
~igher se~si~ivity, specificity and accuracy 
m determmmg pleural malignancy in our 
study than the two previously published 
stud1es on effusion FDG uptake (l6, 27). 
The uniqueness of our study was to 
correlate cytopathological parameters with 
the effusion FDG uptake represented by the 
effusion SUV. 
We found no significant correlation with 
the presence of inflammatory cells, even 
A 
::J' 
-§, 
~ 
~ 
Q) 
::J 
~ 
i 
::J 5 
~ 
~ 
"O 
tii 
U5 0 
B 
• 
• 
• 
p = 0.001 
• • 
-
'----;::;:-::-;::::r~:----:-~~~-
B en i g n effusion Malignant effusion 
Cytopathological diagnosis 
• 
• 
.. • 
p < 0.001 
• • 
SUV of patients with 
benign (n = 33) versus malignant effusions 
(n = 17) 
non-small cell Jung carcinoma with benign 
(n = 18) versus malignant effusions (n = G) 
Nuklearmedizin 5/2012 
though such association could be supposed 
from the FDG uptake mechanism, which 
accumulat~s in activated inflammatory 
cells parttcularly neutrophils, activated 
lymph.ocytes and macrophages (14, 17' 22), 
Thus, I~ pleural effusion, only the presence 
of mahgnant cells was associated with in-
creased FDG uptake in contrary to what 
can be observed in many situations where 
FDG is known to be increased by inflam-
matory processes (19) · Moreover, the lower 
SU," threshold in pleural effusion than in 
sohd tumours might be explained by a 
lower tumour cell charge and that FDG 
penetrates pleural cavity by exudation/ 
transudation and not by perfusion. 
!he ~inical management of pleural ef-
fus10ns m cancer patients prompts for the 
de~e:mination of the malignant or benign 
ongm. Indeed, benign effusions are treated 
according to the primary cause, while in 
A 1.00 -------------------------------------J"" 
V 
. ...J"" .... ..r 
0.75 
È 
..s 
'@ 0.50 
1 
I Jl 
0.25 
AUC = 0.81±0.07 
0.00 o~.o~o~-=-o.~25=---~o'.5-o~~o.~75~~j_ 1.00 
1 - Specilicity 
B 1.00 
t 0.50 
c: 
Q) 
(f) 
0.25 
AUC = 0.94±0.05 
0.00 o~.o~o~--=-o.~2s=---~o'.s-o~~o.r75~~1j__.oo 
1 - Specilicity 
. . . ROC analysis (sensitivity versus 1 _ spe-
c1f1c1ty = taise positive rate) of thoracocenteses 
ail patients (n = 50) 
patients with non-small cell Jung carcinoma 
(n = 24) 
malignant effusions symptoms relief can be 
obtained with pleurodesis or may respond 
to chemotherapy in case of lymphoma, 
small ce!! Jung carcinoma or germ cell 
tumours. PET/CT may be used 
® for ex~ludin? the presence of malignant 
cells m patients with known cancers 
when 
- thoracocentesis is not feasible, i.e. 
when there is less than 10-mm of 
pleural effusion on ultrasonography 
(18) or 
- patients are in poor condition keep!n~ in mind that the negativ~ 
pred1ctlve value is 79%, which may 
still be clinically relevant. 
® to identify p~tients with previously un-
detected mahgnant effusion with for in-
stance negative thoracocentesis, whom 
should be referred for thoracoscopy. 
Spe~ifically, in NSCLC, the presence of 
mahgna~t effu~io~ is associated with a poor 
prognos1s and lim1ted survival of 2-6 months 
(30). Including information on performance 
status may be of high clinical relevance. In-
?eed, determining whether a pleural effusion 
~n a ~SCLC patient with poor performance 
mdex1s of malignant origin or not may not be 
necessary ( 30), On the contrary, identifying a 
subset of patients with better survival may be 
of critical importance (30). Thus, due to its 
high negative predictive value (94% in our 
s~dy), ~ET/CT may help to select patients 
';Ith satisfactory performance index and a 
likely betterprognosis in whom thoracoscopy 
could be avoided. 
'.atients with satisfactory performance 
index, . negative cytology and positive 
PET/CT in pleural effusion could be referred. 
for t~oracoscopic evaluation of the pleurai 
effusion before being referred to surgery to 
exclude a taise negative result of the 
thoracocentesis. 
The exact place of PET/CT in the manage-
ment of patients with cancer presenting 
pleural effusion would need to be deter-
mined in a prospective study to see where it 
c~n. be adequately implemented in the 
cl1111cal management (21). As mentioned 
further studies would be needed: ' 
® on patients with pleural effusion and 
cancers other than NSCLC; and 
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111 on whether using a different or modi-
fied protocol for investigating pleural ef-
fusion with PET /CT would be of interest 
to appreciate the role of exudation on 
pleural effusion SUV values. 
® genetic analysis (DNA methylation, 
gene expression testing, aneuploidy 
detection, comparative genomic 
hybridization analysis) and 
® immunologie and molecular cyto-
genetic testing for lymphoma (13, 30). 
Our study was retrospective, but the nuclear 
medicine physicians and radiologists were 
blinded to the cytopathology results. More-
over, in a few examinations (n = 18), thora-
cocentesis was performed before the PET/ 
CT and may have induced an inflammatory 
response that may theoretically increase the 
FDG uptake in the pleural effusion. How-
ever, there was no significant difference in 
SUV in benign pleural effusion when thora-
cocentesis was performed before PET/CT 
imaging as compared to the group where 
thoracocentesis was performed thereafter 
(1.5±0.5, n == 10 vs. 1.8±0.6, n==23; p == 
0.17). Also, the time interval of 60 days be-
tween the PET/CT and thoracocentesis 
might be seen as a limitation, but similar dif-
ferences in SUV between malignant and be-
nign effusions were observed when this in-
terval waslimited to 30 days (3,9±4.0,n == 15 
vs. 1.7±0.7, n == 21; p==0.019), as well as 
nearly identical Spearman ranks correlation 
between the presence of malignant cells and 
SUV (p == 0.52, n == 36; p == 0,0012). 
The addition of these special studies or dif-
ferent smear techniques, as performed in 
our study, can improve the rate of yield of 
thoracocentesis above 80% (5, 26). There-
fore, the state-of-the-art augmented cyto-
pathology techniques employed in our 
study cannot be considered as a limitation 
as compared to thoracoscopic biopsy. 
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Recordon, B.S., Mr. Jérôme Malterre, B.S. 
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in performing the PET/CT studies. They 
would also like to thank the cytotechnol-
ogists of the Pathology institute in Laus-
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Rochat for her help in reviewing the slides. 
They are also indebted to Mr. Daniel Kalo-
tay, B.S., M.S. for editorial assistance. 
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Leenaards Foundation (Lausanne, Switzer-
land). 
Finally, it should be mentioned that the 
reported sensitivities and specificities are 
relatively independent on the prevalence of 
malignant pleural effusions in the observed 
population ( 4) and would be applicable to 
other centres, in contrary to positive and 
negative predictive values, which would 
more strongly depend on the prevalence of 
malignant pleurâl effusions in the observed 
population (34% in our population). 
The authors declare, that they have no 
conflict of interest. 
The fact that thoracocentesis was used 
and results were not verified by thoraco-
scopic biopsy might be seen as a limitation. 
Indeed, the diagnostic yield of thoracocen-
tesis with traditional cytology has been 
commonly described to be around 65% in 
the literature as compared to thoraco-
scopy-obtained or imaged-guided biopsy 
( 13), although in our series less than 10% of 
the patient had pleural lesions suitable for 
an imaged-guided biopsy. The true value of 
thoracocentesis remains controversial, 
with values ranging from 62-90% (3) or 
40-87% with a mean of 60% (20) in the 
consensus of the American and British 
Thoracic Societies. However, it is probably 
underestimated, as many additional cyto-
pathology techniques can be added to pleu-
ral fluid examination, such as 
111 tumoural marker detection ( carcino-
embryonic antigen, carbohydrate 
antigen 15-3, cancer antigen 125), 
© Schattauer 2012 
Pleural effusion SUV was a significant and 
independent predictor of the presence of 
malignant cells in patients with known 
cancers with a high specificity, compared to 
common cytopathological parameters. 
PET/CT pleural FDG effusion uptake had a 
good specificity and high negative pre-
dictive value especially in patients with 
NSCLC. This allows clinicians to anticipate 
thoracocentesis results or to identify the 
subpopulation requmng thoracoscopic 
biopsy (in case of positive PET/CT with 
negative thoracocentesis findings). 
This would be of clinical importance in pa-
tients with NSCLC, as malignant effusion 
would contraindicate surgery. Larger 
prospective studies are warranted to con-
firm our findings, preferably in a multi-
centre trial. 
The authors would like to thank the tech-
nologists Mrs. Fatima El-Hakmaoui, B.S. 
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